HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%

HOOKIPA Pharma Inc.

Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.
Revenue $7.4M (Q4) and $20.1M (FY2023); R&D expenses $21.2M and $86.4M.
Cash and equivalents $117.5M at Dec 31, 2023, including $71M from capital raises and $15M in milestones.
HB-200 + pembrolizumab showed 42% objective response rate in 1L HPV16+ HNSCC; pivotal trial to start 2024.
Roche terminated HB-700 collaboration; HOOKIPA to regain rights; IND filing by April 2024 triggers final milestone.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HOOKIPA Pharma Inc. reported financial results for the fourth quarter and full year 2023.

Period: the fourth quarter and full year 2023
Result: reported results

Exact text from the filing

On March 22, 2024, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-003735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.